Barclays PLC cut its holdings in Silence Therapeutics plc (NASDAQ:SLN – Free Report) by 40.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,333 shares of the company’s stock after selling 2,237 shares during the quarter. Barclays PLC’s holdings in Silence Therapeutics were worth $61,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors also recently modified their holdings of the company. Marshall Wace LLP boosted its holdings in Silence Therapeutics by 7.3% in the second quarter. Marshall Wace LLP now owns 149,397 shares of the company’s stock valued at $2,839,000 after acquiring an additional 10,206 shares in the last quarter. Millennium Management LLC lifted its position in shares of Silence Therapeutics by 91.2% in the 2nd quarter. Millennium Management LLC now owns 782,941 shares of the company’s stock worth $14,876,000 after purchasing an additional 373,523 shares during the period. Quarry LP bought a new stake in shares of Silence Therapeutics during the 2nd quarter valued at about $114,000. Point72 Asset Management L.P. increased its position in shares of Silence Therapeutics by 1,686.6% during the second quarter. Point72 Asset Management L.P. now owns 146,500 shares of the company’s stock valued at $2,784,000 after buying an additional 138,300 shares during the period. Finally, Values First Advisors Inc. purchased a new position in shares of Silence Therapeutics during the third quarter valued at about $56,000. 98.73% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several research firms have weighed in on SLN. William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th. BMO Capital Markets restated an “outperform” rating on shares of Silence Therapeutics in a research note on Monday, December 2nd. Morgan Stanley reaffirmed an “overweight” rating and issued a $49.00 price target on shares of Silence Therapeutics in a research note on Tuesday, October 8th. Chardan Capital reissued a “buy” rating and set a $55.00 price objective on shares of Silence Therapeutics in a research report on Tuesday, December 10th. Finally, HC Wainwright restated a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a report on Monday, December 9th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $57.20.
Silence Therapeutics Stock Up 5.2 %
SLN stock opened at $5.69 on Friday. The business has a 50 day moving average of $6.86 and a 200 day moving average of $14.35. Silence Therapeutics plc has a twelve month low of $4.82 and a twelve month high of $27.72. The firm has a market cap of $170.30 million, a PE ratio of -3.62 and a beta of 1.08.
Silence Therapeutics Profile
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
See Also
- Five stocks we like better than Silence Therapeutics
- Stock Average Calculator
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- What is Short Interest? How to Use It
- 3 Buy-and-Hold Stocks for Long-Term Growth
- 3 Best Fintech Stocks for a Portfolio Boost
- Despite Short-Term Risks Freeport McMoran Worth a Look
Want to see what other hedge funds are holding SLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Silence Therapeutics plc (NASDAQ:SLN – Free Report).
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.